TRIAL OF CANNABIDIOL FOR DRUG-RESISTANT SEIZURES IN THE DRAVET SYNDROME
DEVISNKY O., CROSS J.H., LAUX L., MARSH E., MILLER I., NABBOUT R., SHEFFER IE., THIELE EA. & WRIGHT S.
N ENGL J MED. 2017 MAY 25; 376(21):2011-2020. DOI: 10.1056/NEJMOA1611618.
A double-blind, placebo-controlled trial on 120 children and young adults with the Dravet syndrome and drug-resistant seizures shows that cannabidiol reduces the frequency of convulsive seizures.
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
At ANTG, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU. Interested in investing in medicinal cannabis? Read what sets ANTG apart.